Cargando…
PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.
Autores principales: | Koster, K.-L., Messerich, N.-M., Volken, T., Cogliatti, S., Lehmann, T., Holbro, A., Benz, R., Graf, L., Demmer, I., Jochum, W., Silzle, T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431484/ http://dx.doi.org/10.1097/01.HS9.0000851072.40949.cf |
Ejemplares similares
-
P1053: ALBUMIN AND C-REACTIVE PROTEIN PROVIDE PROGNOSTIC INFORMATION INDEPENDENTLY FROM MIPSS70 IN OVERT MYELOFIBROSIS. A RETROSPECTIVE STUDY.
por: Messerich, N.-M., et al.
Publicado: (2022) -
Prognostic Significance of the Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) in Patients with Myelofibrosis: A Retrospective Study
por: Koster, Kira-Lee, et al.
Publicado: (2023) -
CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70—A Retrospective Study
por: Messerich, Nora-Medea, et al.
Publicado: (2023) -
Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020) -
ATS MD’s in 2016
por: Fartoukh, Stephane, et al.
Publicado: (2016)